Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNDX Syndax Pharmaceuticals

Trading 11-05 11:19:40 EST

9.95

-0.50

-4.78%

High10.47	Low9.90	Vol1.46M
Open10.38	D1 Closing10.45	Amplitude5.45%
Mkt Cap895.78M	Tradable Cap805.82M	Total Shares90.03M
T/O14.80M	T/O Rate1.80%	Tradable Shares80.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals","latestPrice":9.95,"timestamp":1793895579883,"preClose":10.45,"halted":0,"volume":1459863,"delay":0,"changeRate":-0.04784688995215311,"floatShares":80987300,"shares":90028256,"eps":-2.37,"marketStatus":"Trading","change":-0.5,"latestTime":"11-05 11:19:40 EST","open":10.38,"high":10.47,"low":9.9,"amount":14804324.696700001,"amplitude":0.054545,"askPrice":9.97,"askSize":311,"bidPrice":9.94,"bidSize":93,"shortable":0,"etf":0,"ttmEps":-2.37,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793912400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1456981200000,"exchange":"NASDAQ","adjPreClose":10.45,"preHourTrading":{"tag":"盘前","latestPrice":10.38,"preClose":10.45,"latestTime":"09:29 EST","volume":8149,"amount":85610.680383,"timestamp":1793888999999,"change":-0.07,"changeRate":-0.006699,"amplitude":0.042038},"postHourTrading":{"tag":"盘后","latestPrice":10.4077,"preClose":10.45,"latestTime":"19:55 EST","volume":191617,"amount":2002089.3302,"timestamp":1793840115471,"change":-0.0423,"changeRate":-0.004048,"amplitude":0.025033},"volumeRatio":0.844769,"impliedVol":0.6181,"impliedVolPercentile":0.5219},"requestUrl":"/m/hq/s/SNDX","defaultTab":"news","newsList":[{"id":"2681078041","title":"Syndax Pharmaceuticals Is Down 51% Even Though Sales Rose","url":"https://stock-news.laohu8.com/highlight/detail?id=2681078041","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681078041?lang=en_us&edition=fundamental","pubTime":"2026-11-05 16:41","pubTimestamp":1793868092,"startTime":"0","endTime":"0","summary":"SSasha JovanovicNovember 5, 2026","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-is-down-51-even-though-sales-rose","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-is-down-51-even-though-sales-rose","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681098100","title":"Revolution Medicines Q3 Revenue Reaches $198 Mln After Rasonque Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2681098100","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681098100?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:25","pubTimestamp":1793827514,"startTime":"0","endTime":"0","summary":"Revolution Medicines Q3 revenue reaches $198 mln after RASONQUE launchOverviewU.S. oncology drugmaker reported Q3 net product revenue of $198 mln after RASONQUE launchCompany posted Q3 net loss of $40","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L1DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","SG9999013999.USD","LU1674673691.USD","LU2236285917.USD","BK4585","LU0154245756.USD","IE0009354923.USD","LU2065171311.SGD","TBXU","LU0061475181.USD","LU0154245673.USD","LU1674673428.USD","IE00B4R5TH58.HKD","VRTX","LU1585245621.USD","IBB","LU2362540622.SGD","PBE","BK4533","CANC","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","SNDX","BK4532","GNMX","LU0256863811.USD","LU1035775433.USD","BBH","RVMD","IDNA","LU0889565916.HKD","SG9999001176.SGD","IE00BZ9MQY76.HKD","LU0234570918.USD","IBBQ","PTH","IE0009355771.USD","NBIX","BIB","LU2324357040.USD","LU1778281490.HKD","LU2237438978.USD","LU2065171402.SGD","LU0417517546.SGD","LU1430594728.SGD","IE0002270589.USD","BK4139","LU2065169927.USD","IE00B894F039.SGD","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681671630","title":"Syndax Grants Five New Employees Options to Buy up to 213,500 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2681671630","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681671630?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:07","pubTimestamp":1793826430,"startTime":"0","endTime":"0","summary":"Syndax Grants Five New Employees Options to Buy Up to 213,500 SharesSyndax Pharmaceuticals granted stock options covering up to 213,500 shares to five new employees on Nov. 4, 2026.The awards fall und","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL4fhrlS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU0314104364.USD","NDAQ","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","IE00BQXX3F31.USD","BCDF","SG9999014005.SGD","BK4588","BK4139","IE00BN0W2W23.USD","LU2095319765.USD","BK4585","IE00BN0W2V16.EUR","SNDX","SG9999014013.SGD","IE00BQXX3D17.EUR","BK4112","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681839067","title":"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2681839067","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681839067?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:01","pubTimestamp":1793826060,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/04/3395767/0/en/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","MNQmain","QQQ","QQQA",".IXIC","JEPQ","QID","QQQJ","QQQY","IYW","QDTE","QYLG","TECS","PSQ","NQmain","FTEC","SNDX","ONEQ","GPIQ","NDX","BK4139","03086","TQQQ","SQQQ","QQQM","QQQE","TQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680505200","title":"Syndax Reports High Remission Rates in Frontline Revumenib Combination Trials Ahead of ASH 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2680505200","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680505200?lang=en_us&edition=fundamental","pubTime":"2026-11-04 22:03","pubTimestamp":1793801034,"startTime":"0","endTime":"0","summary":"Syndax reports high remission rates in frontline revumenib combination trials ahead of ASH 2026Syndax Pharmaceuticals will report revumenib and axatilimab data at the American Society of Hematology me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDLp4K3r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","SG9999014039.USD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","NDAQ","IE00BQXX3F31.USD","BCDF","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","SNDX","LU0314104364.USD","IE00B64PRP62.GBP","BK4139","BK4585","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4588","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680567280","title":"Geron Q3 Operating Income Beats Estimates, Rytelo Revenue up 5% Sequentially","url":"https://stock-news.laohu8.com/highlight/detail?id=2680567280","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680567280?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:31","pubTimestamp":1793795501,"startTime":"0","endTime":"0","summary":"Geron Q3 operating income beats estimates, RYTELO revenue up 5% sequentiallyOverviewUS hematology biopharma's Q3 operating income beat analyst expectationsRYTELO product revenue rose 5% from Q2Company","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX","SNDX","LU0154245756.USD","ZVRA","LU0889565916.HKD","BK4007","GERN","LU2065170008.USD","LU0154245673.USD","LU2324357040.USD","LU2065171311.SGD","LU0109394709.USD","LU2065169927.USD","LU2065171402.SGD","LU0823416689.USD","BK4139","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680699056","title":"Netherlands' uniQure Q3 Revenue Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2680699056","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680699056?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:22","pubTimestamp":1793794968,"startTime":"0","endTime":"0","summary":"Netherlands' uniQure Q3 revenue misses estimatesOverviewNetherlands gene therapy firm's Q3 revenue rose yr/yr but missed analyst expectationsQ3 net loss narrowed compared to prior-year periodCompany's","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0MY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","IE00B19Z9Z06.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","LU0079474960.USD","BK4588","BBH","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE00B19Z9P08.USD","IE0009355771.USD","IE00B19Z3B42.SGD","LU1585245621.USD","BK4566","LU1093756325.SGD","BMRN","IBBQ","IDNA","GNMX","LU0109394709.USD","LU0320765992.SGD","LU0058720904.USD","LU2462157665.USD","LU0823416689.USD","LU0889565916.HKD","LU2456880835.USD","SG9999001176.USD","LU0234570918.USD","PBE","IE00BJJMRZ35.SGD","TBXU","LU1674673428.USD","QURE","LU1035775433.USD","LU1430594728.SGD","BIB","LU1674673691.USD","VRTX","IE0002141913.USD","BK4532","IE00B894F039.SGD","BK4567","IBB","SNDX","LU1069344957.HKD","LU2417539215.USD","BK4533","LU2236285917.USD","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680405666","title":"BioCryst Q3 Revenue Rises 13% on Orladeyo Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2680405666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680405666?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:22","pubTimestamp":1793794934,"startTime":"0","endTime":"0","summary":"BioCryst Q3 revenue rises 13% on ORLADEYO salesOverviewU.S. rare disease drugmaker's Q3 revenue rose 13% yr/yr, driven by ORLADEYO sales and CareMed transitionQ3 net income increased significantly fro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0MA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","LU2324357040.USD","SNDX","BK4547","TVTX","MIRM","BK4139","BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680177704","title":"Zevra Therapeutics Q3 Revenue Rises 45% on Miplyffa Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2680177704","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680177704?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:18","pubTimestamp":1793740716,"startTime":"0","endTime":"0","summary":"Zevra Therapeutics Q3 revenue rises 45% on MIPLYFFA salesOverviewU.S. rare disease drugmaker's Q3 revenue rose 45% yr/yr, beating analyst expectationsCompany posted net income in Q3, reversing a loss ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nL2N46K15C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245673.USD","LU2065171311.SGD","BK4007","BK4566","SNDX","LU2065170008.USD","IE00B7SZLL34.SGD","ZVRA","BMRN","BK4139","LU0320765992.SGD","LU2065171402.SGD","IE00B19Z3B42.SGD","LU0823416689.USD","LU0889565916.HKD","LU0154245756.USD","LU0109394709.USD","IE00B19Z3581.USD","IE0002270589.USD","NBIX","LU2065169927.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680777651","title":"Ardelyx Q3 Product Revenue Rises 19%, Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2680777651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680777651?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:11","pubTimestamp":1793740264,"startTime":"0","endTime":"0","summary":"Ardelyx Q3 product revenue rises 19%, loss narrowsOverviewBiopharmaceutical company's Q3 product revenue grew 19% yr/yr to $125.5 mlnCompany reported Q3 net loss of $0.7 mln, slightly narrower than la","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nL2N46K13O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","BK4139","LU0124676726.USD","LU0689626769.HKD","LU2065169927.USD","BK4149","LU2065171311.SGD","BK4533","LU2463526074.USD","MADE","TVTX","LU0320765992.SGD","LU2324357040.USD","BK4588","LU0203345920.USD","IE000M9KFDE8.USD","LU0889565916.HKD","LU0069063385.USD","LU0203347892.USD","LU2065170008.USD","ARDX","LU0057025933.USD","LU0109394709.USD","NBIX","BK4567","LU0154245673.USD","LU0154245756.USD","LFSC","LU0823416689.USD","SNDX","CMI","LU0472753341.HKD","BK4585","LU2065171402.SGD","LU0511384066.AUD","LU0289961442.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680457728","title":"Syndax Pharmaceuticals Price Target Cut to $36.00/Share from $38.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2680457728","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680457728?lang=en_us&edition=fundamental","pubTime":"2026-11-03 19:43","pubTimestamp":1793706180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680693740","title":"Syndax price target lowered to $36 from $38 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2680693740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680693740?lang=en_us&edition=fundamental","pubTime":"2026-11-03 19:17","pubTimestamp":1793704636,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Syndax (SNDX) to $36 from $38 and keeps a Buy rating on the shares. The firm sees the rebound in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-price-target-lowered-to-36-from-38-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-price-target-lowered-to-36-from-38-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680201716","title":"Syndax Pharmaceuticals, Inc. : Jefferies Cuts Target Price to $17 from $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2680201716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680201716?lang=en_us&edition=fundamental","pubTime":"2026-11-03 12:31","pubTimestamp":1793680295,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nFWN46J2LW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680992487","title":"Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q3 Net Loss $0.55, vs. FactSet Est of $0.50 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2680992487","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680992487?lang=en_us&edition=fundamental","pubTime":"2026-11-03 06:37","pubTimestamp":1793659036,"startTime":"0","endTime":"0","summary":"Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q3 Net Loss $0.55, vs. FactSet Est of $0.50 Loss","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680952747","title":"Syndax Forecasts 2026 R&D and SG&A Expenses of $400 Million, Excluding $50 Million in Stock Option Expense","url":"https://stock-news.laohu8.com/highlight/detail?id=2680952747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680952747?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:43","pubTimestamp":1793655783,"startTime":"0","endTime":"0","summary":"Syndax forecasts 2026 R&D and SG&A expenses of $400 million, excluding $50 million in stock option expenseSyndax Pharmaceuticals forecasts 2026 research and development, selling, general and administr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDL8tyM8w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680931767","title":"Herbalife's Q3 Results Beat Estimates on Asia-Pacific Sales Growth; Lifts FY Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2680931767","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680931767?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:22","pubTimestamp":1793654572,"startTime":"0","endTime":"0","summary":"Herbalife's Q3 results beat estimates on Asia-Pacific sales growth; lifts FY outlookOverviewUS nutrition products seller's Q3 sales rose 6%, beating analyst expectationsAdjusted EPS and adjusted EBITD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nL2N46J10C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4558","HLF","KRYS","LU1988902786.USD","BK4548","BK4588","LU1064131342.USD","LU2404859741.USD","BK4504","SNDX","GLAM","LU2264538146.SGD","LU2552382215.SGD","BK4533","BK4139","HELX","BK4585","LU0690374615.EUR","LU0690374961.EUR","PSCH","BK4532","LU2552382058.USD","LU2404859667.USD","LU2552382132.HKD","BK4183","EL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680798419","title":"Syndax Pharmaceuticals Q3 Revenue Rises 82% on Cancer Drug Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2680798419","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680798419?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:08","pubTimestamp":1793653697,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Q3 revenue rises 82% on cancer drug salesOverviewUS biopharma firm's Q3 revenue rose 82% yr/yr, driven by Revuforj and Niktimvo salesQ3 net loss narrowed yr/yr but missed analys","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nL2N46J0YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","SNDX","BK4588","LU0203347892.USD","LU0109394709.USD","AXSM","BK4585","BK4139","LU0320765992.SGD","LU0124676726.USD","CMI","BK4533","LU0689626769.HKD","LU0203345920.USD","LU0511384066.AUD","LU0472753341.HKD","LU0154245673.USD","LU2324357040.USD","IE000M9KFDE8.USD","BK4149","LU0057025933.USD","LU2463526074.USD","MADE","LU0154245756.USD","LU0289961442.SGD","LU0889565916.HKD","BK4007","PTH","BK4567","LU0069063385.USD","LU0289739343.SGD","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680798511","title":"Syndax Names Aaron A. Ondrey CFO, Effective Nov. 9","url":"https://stock-news.laohu8.com/highlight/detail?id=2680798511","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680798511?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:04","pubTimestamp":1793653484,"startTime":"0","endTime":"0","summary":"Syndax Names Aaron A. Ondrey CFO, Effective Nov. 9Syndax Pharmaceuticals appointed Aaron A. Ondrey chief financial officer, effective November 9, 2026.Outgoing CFO Keith A. Goldan will retire from the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDL7kNKnX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014021.USD","BK4588","LU2210150020.SGD","IE00BQXX3F31.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","SNDX","IE00BQXX3D17.EUR","BK4585","SG9999014005.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","SG9999014013.SGD","BK4139","BCDF","IE00BN0W2W23.USD","IE00BKPKM429.USD","NDAQ","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680798372","title":"Syndax Pharmaceuticals Q3 Operating Expenses USD 125.193 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2680798372","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680798372?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:02","pubTimestamp":1793653321,"startTime":"0","endTime":"0","summary":"BRIEF-Syndax Pharmaceuticals Q3 Operating Expenses USD 125.193 MillionNov 02 (Reuters) - Syndax Pharmaceuticals Q3 net income USD -49.433 million vs. IBES estimate USD -45.2 million.Q3 operating income USD -41.895 million","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nPLXBDLTTV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680384798","title":"Syndax Pharmaceuticals Q3 EPS $(0.55) Misses $(0.49) Estimate, Sales $83.298M Beat $81.850M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2680384798","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680384798?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:01","pubTimestamp":1793653300,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.49) by 12.24 percent. This is a 21.43 percent increase over losses of $(0.70) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/62796660/syndax-pharmaceuticals-q3-eps-0-55-misses-0-49-estimate-sales-83-298m-beat-81-850m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":-0.2703},{"period":"1month","weight":-0.4139},{"period":"3month","weight":-0.4712},{"period":"6month","weight":-0.5137},{"period":"1year","weight":-0.3192},{"period":"ytd","weight":-0.5026}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0104},{"period":"3month","weight":-0.0023},{"period":"6month","weight":0.0396},{"period":"1year","weight":0.1356},{"period":"ytd","weight":0.1245}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.039298},{"month":2,"riseRate":0.7,"avgChangeRate":0.080379},{"month":3,"riseRate":0.6,"avgChangeRate":0.053723},{"month":4,"riseRate":0.363636,"avgChangeRate":0.005788},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.025528},{"month":6,"riseRate":0.545455,"avgChangeRate":0.007318},{"month":7,"riseRate":0.545455,"avgChangeRate":0.003097},{"month":8,"riseRate":0.636364,"avgChangeRate":0.097617},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.030865},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.095613},{"month":11,"riseRate":0.545455,"avgChangeRate":0.020433},{"month":12,"riseRate":0.5,"avgChangeRate":0.035938}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Syndax Pharmaceuticals,SNDX,Syndax Pharmaceuticals股票,Syndax Pharmaceuticals股票老虎,Syndax Pharmaceuticals股票老虎国际,Syndax Pharmaceuticals行情,Syndax Pharmaceuticals股票行情,Syndax Pharmaceuticals股价,Syndax Pharmaceuticals股市,Syndax Pharmaceuticals股票价格,Syndax Pharmaceuticals股票交易,Syndax Pharmaceuticals股票购买,Syndax Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}